She stated that “It is interesting that my speech resembled the stressed speech in young children who have had tumors removed from the cerebellum”.\n\nMethods In this article, we intend to review and extensively document both postoperative cerebellar mutism and autistic spectrum disorder.\n\nResults We reviewed the clinical and neurological findings, etio-pathogenesis, neuroanatomy, mechanisms of development, and similarities between the etio-pathogenesis of both diseases.\n\nConclusions Cerebellar lesions can produce
mutism and dysarthria, symptoms sometimes seen in autistic spectrum disorder. In mammals, cerebellar lesions disturb motivated behavior and reduce social interactions, functions that are disturbed in autistic spectrum disorder and cerebellar mutism. The cerebellum and two regions within the frontal lobes are active in certain language tasks. Language is abnormal in autistic Selleck HSP990 spectrum disorder PF-00299804 mouse and cerebellar mutism.”
“To ascertain the clinicopathological process underlying dysglycemia induced by the fluoroquinolone antibacterial gatifloxacin (GFLX), we orally administered 100 or 300 mg/kg/day to male clinically healthy (naive) or spontaneous type II (diabetic) Goto-Kakizaki rats for 15 days (days 1 to 15). Treatment of naive rats with GFLX led to decreased blood
glucose concentrations at 100 mg/kg/day on day 1. In diabetic animals, markedly increased blood glucose concentrations were noted from 100 OICR-9429 mg/kg/day on day 3, and all of the animals given 300 mg/kg/day died or were killed because of moribund conditions by day 9. In a glucose tolerance test, serum insulin concentrations decreased significantly in naive rats receiving 300 mg/kg/day. Microscopically, cytoplasmic vacuolations of the pancreatic islets were observed in naive rats receiving 300 mg/kg/day, and congestion and/or hemorrhage were additionally noted in diabetic rats given 100 mg/kg/day or
more. In toxicokinetics with 100 mg/kg/day, AUC(0-8) (hr). values for GFLX were higher in diabetic rats than in naive rats, and relatively high serum GFLX concentration’s at 8 hr post-dose and extraordinarily high pancreatic GFLX concentrations were also observed in diabetic rats. These results demonstrate that hypoglycemia or hyperglycemia induced by GFLX is associated with higher distribution and retention of GFLX in the pancreas, leading to disturbed insulin secretion.”
“Objectives: To assess the yield of medical record review to recover missing data originally collected by questionnaire, to analyze the agreement between these two data sources and to determine interobserver variability in clinical record review.\n\nMethods: We analyzed data from a birth cohort of 8,127 women who were consecutively recruited after giving birth from 2005-2006. Recruitment was conducted at all public maternity units of Porto, Portugal.